Carie Boyd
- Company typePrivate
- Founded1965
- HeadquartersIrving, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Carie Boyd firmographics
Firmographics- Name
- Carie Boyd
- Legal name
- Carie Boyd Pharmaceuticals
- Website
- https://carieboyd.com
- Company type
- Private
- Founded year
- 1965
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Where Carie Boyd is headquartered
LocationHeadquarters
- HQ city
- Irving
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Carie Boyd business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Office-Use Medications (503B): Bulk compounded medications sold to licensed healthcare providers, clinics, hospitals, and group purchasing organizations without patient names or prescriptions. Providers order through customer portal for office administration.
- Patient-Specific Prescriptions (503A): Compounded medications dispensed pursuant to patient-specific prescriptions from licensed healthcare providers. Medications shipped directly to patients.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Carie Boyd product offering
Product offeringCore offering
Carie Boyd Pharmaceuticals is a compounding pharmaceutical manufacturer operating both an FDA-registered 503B outsourcing facility (Irving, TX) for office-use medications and a 503A specialty compounding pharmacy (Denton, TX) for patient-specific prescriptions. The company compounds bioidentical hormone pellets, injections, oral hormones, topical creams, sublingual formulations, anesthetics, dermatology preparations, sexual wellness products, weight management compounds, and dental and veterinary medications. Its differentiated technology includes an automated pellet manufacturing process with industry-leading potency precision under 1.5% variance, proprietary SubMagna sublingual base for semaglutide, and cGMP-compliant production meeting Title 21 CFR parts 210 and 211 standards.
Product overview
Carie Boyd Pharmaceuticals is a compounding pharmacy offering a diverse portfolio of office-use and patient-specific medications through two facilities: a 503A specialty compounding pharmacy and an FDA-registered 503B outsourcing facility. The product portfolio centers on hormone replacement therapy (HRT) delivered via pellets, injections, oral capsules/tablets, topical creams, and sublingual formulations. Core HRT products include hormone pellets (testosterone, estradiol, testosterone combo), hormone injections (testosterone cypionate, testosterone cypionate/propionate), oral hormones (progesterone and estradiol in various forms), and hormone creams (bi-estrogen, estradiol, estriol, progesterone). Supporting therapies include adjunctive hormone products (anastrozole, clomiphene, DHEA), sexual wellness medications (sildenafil, tadalafil), dermatology/aesthetics preparations, hair/scalp health treatments (Formula 82D/F/M), weight management (semaglutide sublingual, naltrexone), anesthetics (BLT cream, lidocaine products), dental anesthetics, and veterinary medications. Both 503A and 503B operations comply with USP standards and cGMP requirements respectively.
Differentiator
Problem solved
Functional benefit
Products and services
- Hormone Pellets (Estradiol, Testosterone, Testosterone Combo) Subcutaneous implantable bioidentical hormone pellets for healthcare providers and patients needing long-acting hormone replacement therapy; delivers steady hormone release over 3-6 months.
- Hormone Injections (Testosterone Cypionate, Testosterone Cypionate/Propionate) Injectable bioidentical hormone products in multi-dose vials validated for 12 months, intended for healthcare providers and patients requiring injectable hormone therapy.
- Oral Hormones (Progesterone Capsules, Progesterone Sublingual Tablets, Estradiol Sublingual Tablets, Progesterone Troche) Bioidentical oral and sublingual hormone preparations for healthcare providers and patients; available as capsules, sublingual tablets, and troches.
- Hormone Creams (Bi-Estrogen Cream, Estradiol Cream, Estriol Cream, Progesterone Cream) Topical bioidentical hormone creams with 180-day beyond-use date, formulated for healthcare providers and patients who prefer transdermal hormone delivery.
- Adjunctive Hormone Therapy (Anastrozole, Clomiphene, DHEA) Adjunctive hormone therapies for healthcare providers managing patients on primary HRT; available as capsules and drops.
- Sexual Wellness Products (Sildenafil, Tadalafil, Oxytocin, Arousal Cream) Compounded sexual wellness formulations in multiple delivery formats for healthcare providers treating men and women.
- Dermatology & Aesthetics (Hyperpigmentation, Anti-Aging, Rosacea, Acne, Scars, Nail Fungus, Warts, Hyperhidrosis) Prescription-only compounded dermatology preparations for healthcare providers treating a range of skin conditions with customized multi-ingredient formulations.
- Hair & Scalp Health (Formula 82D, 82F, 82M, Dutasteride, Finasteride, Minoxidil/Finasteride) Compounded hair regrowth and scalp health topicals and oral capsules for healthcare providers prescribing hair loss treatments.
- Weight Management (Semaglutide Sublingual, Naltrexone, Bupropion/Naltrexone) Compounded weight management products for healthcare providers, including a proprietary semaglutide sublingual suspension alongside naltrexone and combination capsules.
- Anesthetics (BLT Cream, Sodium Bicarbonate, Lidocaine with Epinephrine) Compounded topical and injectable anesthetics for office-use by healthcare providers across urgent care, surgery, and emergency settings.
- Dental Anesthetics (Profound Gel, Profound Gel Thickened, Profound Gel with Phenylephrine) Compounded dental anesthetic gels and oral pastes in dye-free formulations for dental offices and oral surgery centers.
- Veterinary Medications (EKT Otic, Methimazole, Metronidazole, Doxycycline) Compounded medications for veterinary use, available in customizable strengths and flavors.
- 503B Outsourcing Facility Services FDA-registered 503B outsourcing facility service delivering bulk office-use compounded medications to licensed healthcare providers, clinics, hospitals, and group purchasing organizations without patient-specific prescriptions.
- 503A Compounding Pharmacy Services 503A specialty compounding pharmacy service for patient-specific prescriptions, dispensing personalized compounded medications nationwide from the Denton, TX location with a 2-day standard turnaround.
Quantifiable outcome
- Industry-leading potency variance of less than 1.5% (vs 10% permitted by many compounders)
- +5 more outcomes
Companies that use Carie Boyd
Customer profileNamed customers8 records
Segments7 records
Ideal customer profiles1 record
Carie Boyd technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature4 records
Carie Boyd partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
Carie Boyd competitors and assessment
Company assessmentDirect peers
- Pentec Health: Specialty pharmacy and 503B outsourcing facility providing sterile compounded medications, including intrathecal and parenteral therapies; overlaps with Carie Boyd on provider-channel sterile/non-sterile compounding.
- SottoPelle: Pioneer in subcutaneous hormone pellet therapy for men and women; competes with Carie Boyd's estradiol, testosterone, and testosterone combo pellet products in the same provider-prescribed channel.
- Empower Pharmacy: Largest 503A/503B compounding pharmacy in the United States, offering hormone replacement, weight loss, and sterile injectable compounds; directly comparable to Carie Boyd across business model, customer base (providers and patients), and product mix.
- BioTE Medical: Direct competitor in subcutaneous bioidentical hormone pellet therapy with a national provider training and distribution network; competes head-to-head with Carie Boyd's flagship pellet line.
- QuVa Pharma: 503B outsourcing facility focused on sterile injectable and non-sterile compounded medications for hospitals and clinics; comparable in regulatory posture (cGMP, FDA-registered) and office-use distribution model.
- Avella Specialty Pharmacy: Specialty and compounding pharmacy accredited by URAC and ACHC, offering sterile compounds, HRT, and dermatology preparations; overlaps with Carie Boyd on provider-served patient-specific prescriptions.
- Leiters: FDA-registered 503B outsourcing facility producing sterile and non-sterile compounded medications for hospitals and clinics; comparable in regulatory positioning and provider-channel distribution.
- Olympia Pharmaceuticals: FDA-registered 503B outsourcing facility providing office-use compounded medications to healthcare providers; closely aligned with Carie Boyd's Irving 503B operations in regulatory structure and customer motion.
Broad incumbents
- Fagron: Global leader in pharmaceutical compounding with a broad portfolio of APIs, bases, and compounded products serving both 503A and 503B channels; overlaps with Carie Boyd on HRT, dermatology, and veterinary compounding.
Emerging players
- Wedgewood Pharmacy: Largest US veterinary compounding pharmacy; comparable to Carie Boyd's veterinary line (EKT Otic, methimazole, metronidazole) on formulation expertise and prescriber-channel distribution for animal-health compounds.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Carie Boyd social profiles
Digital presenceCarie Boyd compliance and trust
Trust signalCompliance5 records
Carie Boyd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Carie Boyd leadership team
Management profileNumber of profiles
Carie Boyd funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Carie Boyd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Carie Boyd
What does Carie Boyd do?
Carie Boyd Pharmaceuticals is a compounding pharmaceutical manufacturer operating both an FDA-registered 503B outsourcing facility (Irving, TX) for office-use medications and a 503A specialty compounding pharmacy (Denton, TX) for patient-specific prescriptions. The company compounds bioidentical hormone pellets, injections, oral hormones, topical creams, sublingual formulations, anesthetics, dermatology preparations, sexual wellness products, weight management compounds, and dental and veterinary medications. Its differentiated technology includes an automated pellet manufacturing process with industry-leading potency precision under 1.5% variance, proprietary SubMagna sublingual base for semaglutide, and cGMP-compliant production meeting Title 21 CFR parts 210 and 211 standards.
Is Carie Boyd a public or private company?
Carie Boyd is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Carie Boyd founded?
Carie Boyd was founded in 1965. It employs 101 to 250 people.
Where is Carie Boyd based?
Carie Boyd is headquartered in Irving, United States, in the North America region.
How does Carie Boyd make money?
Two revenue lines are on record. Office-Use Medications (503B) is the primary driver. The others are patient-Specific Prescriptions (503A).
Who are Carie Boyd's main competitors?
Direct peers on record are Pentec Health, SottoPelle, Empower Pharmacy, BioTE Medical, QuVa Pharma, Avella Specialty Pharmacy, Leiters and Olympia Pharmaceuticals. Fagron is listed as a broad incumbent. Wedgewood Pharmacy is listed as an emerging player.
Does Carie Boyd have an API?
No public API is recorded for Carie Boyd.